Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vernakalant SR for prevention of atrial fibrillation recurrence after cardioversion
NL-OMON30473Phase 2Active, not recruiting
- Sponsor
- Cardiome Pharma
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vernakalant in Atrial fibrillation (AFib) (4 arms), sponsored by Cardiome Pharma. Primary endpoints: Time to first documented recurrence of symptomatic sustained atrial fibrillation, Time to first documented recurrence of symptomatic or asymptomatic sustained atrial fibrillation and 5 more. Started Apr 2007; status: active, not recruiting.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON30473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30473.